ORTX News and Press, Orchard Therapeutics plc From 04/24/23

2023-04-24 17:38:49 ET Summary Shares have lost a third of their value over the past year. HSC-based gene therapy Libmeldy is approved in the EU for MLD with a ~$3.5M price tag. Incidence could be higher than initial estimates. Cash position was bolstered with March financing,...

BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic Medicines and Rare Disease Day on Tuesday, April 4, 2023 at 1:35pm ET. A live ...

2023-03-28 14:57:47 ET The following slide deck was published by Orchard Therapeutics plc in conjunction with this event. For further details see: Orchard Therapeutics (ORTX) Investor Presentation - Slideshow'

2023-03-10 15:17:07 ET Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Conference Call March 06, 2023 8:00 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Leslie Melt...

BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its American Depositary Share ("ADS") to ordinary share ratio has been made effective. The ratio ha...

2023-03-06 06:28:59 ET Orchard Therapeutics press release ( NASDAQ: ORTX ): Q4 GAAP EPS of -$0.06 beats by $0.15 . Revenue of $6.97M beats by $1.66M . Cash, cash equivalents and investments as of December 31, 2022, were $143.8 million, with $32.4 million of deb...

2023-03-06 06:16:15 ET Orchard Therapeutics ( NASDAQ: ORTX ) announced up to $188M in strategic financing to drive the commercialization of its gene therapy product, Libmeldy. The firm entered into a securities purchase agreement for the sale of ordinary shares and warrants ...

OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up to $188 million of additional capital upon achievement of key milest...

Proceeds to accelerate commercialization of Libmeldy and advance the company’s HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025 with potential for significant additional capital at increasing valuations ...

BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences: TD Cowen 43 rd Annual Healthcare Conference on March 7, 2023...